Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron and keeping the price target at $725.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Evan Seigerman has given his Buy rating due to a combination of factors including Regeneron’s robust base business and promising developments in their oncology segment. The company’s ability to effectively convert research and development investments into enterprise value growth is a significant factor in this positive outlook.
Additionally, there is cautious optimism surrounding Regeneron’s early-stage pipeline, which could provide further growth opportunities. The strategic financial management, highlighted by a strong cash position and a newly initiated dividend, also supports the confidence in the company’s long-term success in the biotech sector.
In another report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $850.00 price target.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of REGN in relation to earlier this year.